Want to see NBP full AI Analyst Report?
Top Page
NovaBridge Biosciences
(NASDAQ:NBP)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-8.54% Downside)
Action:Reiterated
Date:06/30/26
The score is held down primarily by sustained operating losses, minimal recent revenue, and continued negative operating/free cash flow. The key support is low leverage on the balance sheet, plus modest improvement in 2025 loss and cash outflow versus 2024, but valuation remains challenged by ongoing unprofitability and limited technical/earnings-call data to indicate near-term upside catalysts.
Positive Factors
Low leverage / balance sheet strength
A very low debt load (debt-to-equity roughly 1% in 2025) materially reduces solvency risk and gives management flexibility to fund clinical programs. This structural balance-sheet strength lengthens runway versus peers despite operating losses, supporting multi‑quarter development plans.
Negative Factors
Sustained operating losses
Multi‑year operating losses have eroded earnings capacity and equity, constraining internal funding for R&D and commercialization. Persistent unprofitability increases dependence on external capital, raises dilution risk, and weakens the company's ability to self-fund pivotal trials over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet strength
A very low debt load (debt-to-equity roughly 1% in 2025) materially reduces solvency risk and gives management flexibility to fund clinical programs. This structural balance-sheet strength lengthens runway versus peers despite operating losses, supporting multi‑quarter development plans.
Read all positive factors
NovaBridge Biosciences (NBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$184.61M
Dividend YieldN/A
Average Volume (3M)613.91K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.60
Shares Outstanding115,381,690
10 Day Avg. Volume302,898
30 Day Avg. Volume613,909
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside448.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
NovaBridge Biosciences Business Overview & Revenue Model
Company Description
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific ...
NovaBridge Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 4.49M | -10.70M | 88.03M |
| Gross Profit | 0.00 | 0.00 | 4.49M | -10.70M | 41.59M |
| EBITDA | -13.35M | -373.45M | -344.25M | -356.38M | -2.06B |
| Net Income | -6.61M | -162.26M | -1.47B | -967.52M | -2.33B |
Balance Sheet | |||||
| Total Assets | 37.24M | 1.55B | 368.92M | 4.07B | 878.74M |
| Cash, Cash Equivalents and Short-Term Investments | 30.14M | 1.27B | 311.73M | 3.45B | 670.96M |
| Total Debt | 438.46K | 28.33M | 3.89M | 38.29M | 17.64M |
| Total Liabilities | 4.23M | 84.08M | 126.34M | 1.07B | 163.42M |
| Stockholders Equity | 33.02M | 1.47B | 242.58M | 3.01B | 715.33M |
Cash Flow | |||||
| Free Cash Flow | -20.60M | -384.77M | -73.02M | -1.15B | -1.00B |
| Operating Cash Flow | -20.60M | -384.42M | -72.85M | -1.10B | -973.09M |
| Investing Cash Flow | 104.97M | -992.42M | -107.63M | 458.38M | -727.21M |
| Financing Cash Flow | 57.73M | -2.44M | -8.25M | 42.36M | 593.92M |
NovaBridge Biosciences Technical Analysis
1.64
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NBP, the sentiment is undefined. The current price of 1.64 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for NBP.
NovaBridge Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
NovaBridge Biosciences Corporate Events
NovaBridge Biosciences Sets September 8, 2026 AGM in Shanghai and Highlights 2025 Annual Filing
Jul 24, 2026
NovaBridge Biosciences said on July 24, 2026 that it will hold its annual general meeting of shareholders on September 8, 2026 at its Shanghai office, with holders of ordinary shares and American depositary shares of record as of July 27, 2026 ent...
NovaBridge Biosciences Launches 2026 Omnibus Share Incentive Plan
Jul 17, 2026
On July 13, 2026, NovaBridge Biosciences’ board adopted a new 2026 Omnibus Share Incentive Plan that replaces prior equity compensation schemes and consolidates all new awards under a single framework. The plan initially authorizes issuance ...
NovaBridge Biosciences Names New CEO Amid Broad Board and Executive Shake-Up
Jun 29, 2026
On June 29, 2026, NovaBridge Biosciences announced that Srishti Gupta, MD MPP will become chief executive officer and join the board on July 1, 2026, succeeding outgoing CEO Xi-Yong (Sean) Fu, who resigned effective June 30 and will remain an advi...
NovaBridge Biosciences Replaces PwC With Deloitte as Independent Auditor
Jun 16, 2026
On June 16, 2026, NovaBridge Biosciences’ audit committee dismissed PricewaterhouseCoopers as its independent registered public accounting firm and simultaneously appointed Deloitte Touche Tohmatsu Certified Public Accountants as auditor for...
NovaBridge Wins FDA Fast Track for Givastomig in First-Line Gastric Cancer
Jun 16, 2026
On June 16, 2026, NovaBridge Biosciences announced that the U.S. Food and Drug Administration granted Fast Track Designation to its bispecific antibody givastomig, in combination with nivolumab and chemotherapy, for first-line treatment of HER2-ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.